Status and phase
Conditions
Treatments
About
In this study, treosulfan is evaluated for conditioning in allogenic stem cell transplantation. The procedure and the follow-up are the same as in standard allogenic transplant.
The donor is unrelated (identical HLA). The graft is haematological peripheral blood stem cell.
The conditioning with reduced intensity is: fludarabine (from day -6 to day -2), treosulfan (from day -6 to day -4) and thymoglobuline (from day -2 to day -1).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
AGE: >= 18 years and <= 65 years
Patients with a too high transplant-related mortality (TRM) after standard transplantation (multiple myeloma, chronic lymphoid leukemia, non Hodgkin's lymphoma, myelodysplasia)
Patients with visceral contra-indication for standard transplantation:
Karnofsky score >= 70%
Unrelated donor HLA identical (ABC, DRB1; DQB1)
Signed informed consent
Diagnosis :
Chronic myelogenous leukemia (CML):
Multiple myeloma (MM):
Non-Hodgkin's lymphoma (NHL):
Chronic lymphocytic leukemia (CLL):
Acute myeloid leukemia (AML):
Acute lymphoblastic leukemia (ALL):
Myelodysplastic syndromes (MDS):
For all:
Primary purpose
Allocation
Interventional model
Masking
Loading...
Central trial contact
Mauricette MICHALLET, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal